Landscape Capital Management L.L.C. Invests $705,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

Landscape Capital Management L.L.C. bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 23,428 shares of the biopharmaceutical company’s stock, valued at approximately $705,000.

A number of other large investors have also made changes to their positions in the stock. State Street Corp raised its position in shares of TG Therapeutics by 35.8% in the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after buying an additional 2,398,015 shares during the last quarter. Clearbridge Investments LLC acquired a new stake in TG Therapeutics in the 4th quarter worth about $55,237,000. Principal Financial Group Inc. grew its holdings in TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after buying an additional 725,371 shares during the period. Raymond James Financial Inc. acquired a new position in shares of TG Therapeutics during the 4th quarter valued at about $14,508,000. Finally, Braun Stacey Associates Inc. purchased a new position in shares of TG Therapeutics during the 4th quarter worth about $13,328,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Ratings Changes

TGTX has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Trading Down 5.1 %

NASDAQ TGTX opened at $37.35 on Monday. The stock has a market cap of $5.87 billion, a P/E ratio of -373.46 and a beta of 2.13. The company’s fifty day simple moving average is $35.27 and its 200-day simple moving average is $30.89. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 52 week low of $12.93 and a 52 week high of $43.32.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. Equities research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.